INDIA / PHARMACEUTICALS / Q1FY10 RESULTS UPDATE



Biocon

Alok Dalal (aldalal@mfglobal.com) +91 22 6667 9950

In line quarter, near-term triggers absent

Biocon's Q1FY10 results are in line with estimates. Base business sales growth of 16% is driven by the BMS services contract, which accounted for 30% of Syngene's revenue. Biopharma sales remained weak despite the contribution from API supplies of Mycophenolate Mofetil which begun in May 2009, 50% YoY growth in domestic formulations and favourable currency. Adj PAT witnessed a growth of 17% to Rs 548mn. While Biocon's business is well on its way to emerge as a discovery-led pharma company, its key triggers—business scaleability in insulin, domestic formulations and contract services, coupled with benefits from the partnership with Mylan, as well as potential out-licensing of the oral insulin molecule—will only fructify over the next 18-24 months. We believe the stock lacks near-term triggers and is trading at rich valuations of 17x 1-year forward earnings given a muted earnings growth of 8.4% over FY09-FY11. Maintain Sell.

BMS contribution leads base business growth of 16%

BMS recorded sales of Rs 147mn, contributing 30% to Syngene's sales of Rs 580mn for the quarter. Biopharma reported muted sales growth of 9%, while AxiCorp recorded sales of Rs 1.9bn, a growth of 13% QoQ. Base business gross margins improved over 700bps due to better product mix and lower material cost. However, higher depreciation and interest charges restricted consolidated PAT growth to 17% YoY to Rs 548mn.

Contribution from partnership with Mylan and potential out-licensing of the oral insulin molecule at least 18 months away

According to the management, biosimilar partnership with Mylan for emerging markets will start over the next 18-24 months, while benefits from the product supplies to the regulated markets of US and Europe are at least 3-4 years away. The oral insulin molecule IN-105 is likely to conclude its Phase III trials in the middle of next year and would then be considered for out-licensing, an opportunity at least 18 months away from here.

Valuation and key risks to our call

We value Biocon at 15x 1-year forward earnings to arrive at a price target of Rs 191. Key risks to our Sell call are earlier-than-expected out-licensing of oral insulin molecule IN-105 and higher-than-estimated milestone payments from Mylan for FY10 and FY11.

Valuation summary					
Y/E Mar, Rs mn	FY2007	FY2008	FY2009	FY2010E	FY2011E
Net Sales	9,857	10,538	16,171	19,648	21,631
Growth, %	25.1	6.9	53.5	21.5	10.1
EBIDTA	2,738	2,968	3,318	3,910	4,456
EBIDTA margins, %	27.8	28.2	20.5	19.9	20.6
Core EBIDTA	2,738	2,968	3,318	3,910	4,456
Net profit	1,976	2,311	2,384	2,457	2,762
Net profit margin, %	20.0	21.9	14.7	12.5	12.8
Net Profit (adjusted)	1,976	2,311	2,384	2,457	2,762
EPS, Rs	9.9	11.6	11.9	12.3	13.8
EPS Growth, %	15.3	17.0	3.1	3.1	12.4
PER, x	22.2	18.9	18.4	17.8	15.9
EV/EBIDTA, x	16.6	15.6	14.7	12.7	11.3
EV/Net Sales, x	4.6	4.4	3.0	2.5	2.3
Price/Book Value, x	4.1	3.0	2.9	2.6	2.3
ROIC, %	23.2	23.1	18.5	19.6	19.4
ROE, %	20.2	18.2	15.8	15.2	15.4
Dividend Yield, %	0.7	1.1	1.4	1.6	1.8

Source: Company, MF Global India Research Estimates

Maintain Sell / Rs 219 Target Rs 191 (-12%)

Sector Rating					
OW	Ν	UW			
	Stock Rating				
Buy	Stock Rating Neutral	Sell			
Buy		Sell			

This note should be read for:Q1FY10 results review


Bloomberg code : Reuters code : www.biocon.com	BIOS IN BION.BO
BSE Sensex :	14843
NSE Nifty :	4399

Company data	
O/S shares :	200mn
Market cap (Rs) :	44bn
Market cap (USD) :	902mn
52 - wk Hi/Lo (Rs) :	236 / 87
Avg. daily vol. (3mth) :	1.3mn
Face Value (Rs) :	5

Share holding pattern, %	
Promoters :	60.9
FII / NRI :	6.9
FI/MF:	11.0
Non-Promoter Corp. Holdings :	1.3
Public & Others :	19.8

Price performance, %						
	1mth	3mth	1yr			
Abs	2.8	46.8	16.3			
Rel to BSE	-0.8	9.5	11.1			

Price vs. Sensex



Disclaimer & disclosures

This report must be read with the disclaimer and disclosures on the last page that form part of it

M Global

	Q1FY09	Q1FY10			Growth, %	
	without	without			without	Growth, %
Income Statement, Rs mn	AxiCorp	AxiCorp	with AxiCorp	Axicorp		with AxiCorp
Biopharmaceuticals	2,212	2,405	4,296	1,891	9	94
Contract research	427	667	663	(4)	56	55
Total	2,639	3,072	4,959	1,887	16	88
Enzymes	-	-	-			
Total Sales	2,639	3,072	4,959	1,887	16	88
Expenditure						
Materials and Power costs	1,354	1,352	2,891	1,539	(0)	114
Staff Costs	313	375	526	151	20	68
R&D	109	200	200	-	83	83
Other expenses	223	246	357	111	10	60
Total expenditure	1,999	2,173	3,974	1,801	9	99
EBITDA	640	899	985	86	40	54
EBITDA margin, %	24.3	29.3	19.9	4.6	501bps	-439bps
Depreciation	253	314	324	10	24	28
EBIT, core	387	585	661	76	51	71
Other Income	126	90	94	4	(29)	(25)
EBIT	513	675	755	80	32	47
Interest charges	37	50	56	6	35	51
PBT	476	625	699	74	31	47
Taxes	17	108	137	29	535	706
Minority Interest and loss in asst	(10)	-	14	14	-	
Adj. PAT	469	517	548	45	10	17
Adjustments						
1. Fx (gain)/loss	319	(26)	(28)	(2)	-	
Rep. PAT	150	543	576	47	262	284

Common size (%)

	Q1FY09	Q1FY10		(Change (bps)	
	without	without	Q1FY10		without	Change (bps)
	AxiCorp	AxiCorp	with AxiCorp	Axicorp	AxiCorp	with AxiCorp
Materials and Power costs	51	44	58	82	-730	699
Staff Costs	12	12	11	8	35	-125
R&D	4	7	4	-	23	-10
Other expenses	8	8	7	6	-44	-125
Total expenditure	76	71	80	95	-501	439
EBITDA	24	29	20	5	501	-439

Source: Company, MF Global India Research



Adj. profits and adj NPM (%)

Auj. prome and au	111 W (70)					
	Q1FY09	Q1FY10			Growth, %	
	without	without	Q1FY10		without	Growth, %
Adj. PAT	AxiCorp	AxiCorp	with AxiCorp	Axicorp	AxiCorp	with AxiCorp
Biopharmaceuticals	439	447	478	31	2	9
Contract research	30	70	70	-	133	133
Total	469	517	548	31	10	17

	O1FY09	O1FY10			Change (bps)	
	without	without	Q1FY10		0 . 1 /	Change (bps)
Adj. PAT margin, %	AxiCorp	AxiCorp	with AxiCorp	Axicorp	AxiCorp	with AxiCorp
Biopharmaceuticals	20	19	11	2	-126	-872
Contract research	7	10	11	-	347	353
Total	18	17	11	2	-94	-672

Source: Company, MF Global India Research



FINANCIALS

Income Statement					
Y/E Mar, Rs mn	FY2007	FY2008	FY2009	FY2010E	FY2011E
Net sales	9,857	10,538	16,171	19,648	21,631
Growth, %	25	7	53	22	10
Other income	0	0	0	0	0
Total income	9,857	10,538	16,171	19,648	21,631
Operating expenses	-7,119	-7,570	-12,853	-15,738	-17,175
EBITDA (Core)	2,738	2,968	3,318	3,910	4,456
Growth, %	19.7	8.4	11.8	17.8	14.0
Margin, %	27.8	28.2	20.5	19.9	20.6
Depreciation	-667	-940	-1,103	-1,244	-1,407
EBIT	2,071	2,028	2,215	2,666	3,049
Growth, %	19.7	8.4	11.8	17.8	14.0
Margin, %	27.8	28.2	20.5	19.9	20.6
Interest paid	-98	-102	-177	-244	-270
Other Non-Operating Income	107	376	645	323	304
Non-recurring Items	25	2,334	-1,371	0	0
Pre-tax profit	2,106	4,637	1,306	2,739	3,076
Tax provided	-166	-56	-222	-302	-339
Profit after tax	1,940	4,580	1,084	2,437	2,737
Net Profit	2,001	4,646	1,013	2,457	2,762
MF Net profit	1,976	2,311	2,384	2,457	2,762
Growth, %	15.3	17.0	3.1	3.1	12.4
Net Profit (adjusted)	1,976	2,311	2,384	2,457	2,762
Extraordinary items: Gains/(Losses)	25	2,334	-1,371	0	0
Unadj. shares (m)	200	200	200	200	200
Wtd avg shares (m)	200	200	200	200	200

Cash Flow					
Y/E Mar, Rs mn	FY2007	FY2008	FY2009	FY2010E	FY2011E
Pre-tax profit	2,106	4,637	1,306	2,739	3,076
Depreciation	667	940	1,103	1,244	1,407
Chg in working capital	-2,129	909	18	-981	-854
Total tax paid	-27	-6	-203	-357	-295
Other operating activities	0	0	0	0	0
Cash flow from operating activities	617	6,480	2,224	2,644	3,335
Capital expenditure	-1,544	-2,215	-2,890	-2,125	-2,550
Chg in investments	211	-3,957	1,072	500	0
Chg in marketable securities	0	0	0	0	0
Other investing activities	0	0	0	0	0
Cash flow from investing activities	-1,490	-6,613	-2,014	-1,624	-2,550
Free cash flow	-874	-133	210	1,019	0
Equity raised/(repaid)	313	538	149	0	0
Debt raised/(repaid)	907	-10	12	0	0
Dividend (incl. tax)	-301	-385	-602	-600	-805
Other financing activities	0	0	0	0	0
Cash flow from financing activities	941	142	-189	-600	-805
Net chg in cash	68	9	22	419	-20

MGlobal

Balance Sheet					
As at 31st Mar, Rs mn	FY2007	FY2008	FY2009	FY2010E	FY2011E
Cash & bank	87	96	118	537	516
Marketable securities at cost	0	0	0	0	0
Debtors	3,065	2,591	3,667	4,932	5,754
Inventory	1,613	1,790	3,192	3,679	4,190
Loans & advances	530	869	947	1,183	1,479
Other current assets	0	0	0	0	0
Total current assets	5,295	5,346	7,924	10,331	11,940
Investments	791	4,748	3,676	3,176	3,176
Gross fixed assets	10,149	11,547	14,098	16,158	18,488
Less: Depreciation	-1,712	-2,511	-3,612	-4,730	-6,087
Add: Capital WIP	708	1,382	1,720	1,660	1,830
Net fixed assets	9,145	10,419	12,206	13,088	14,230
Non-current assets	512	276	1,631	1,904	2,054
Total assets	15,776	20,824	25,437	28,548	31,460
Current liabilities	2,912	3,581	7,526	8,789	9,715
Provisions	425	705	806	979	1,101
Total current liabilities	3,337	4,286	8,332	9,769	10,816
Non-current liabilities	1,761	1,771	1,749	1,791	1,838
Total liabilities	5,098	6,057	10,081	11,560	12,655
Paid-up capital	500	500	1,000	1,000	1,000
Reserves & surplus	10,186	14,341	14,107	15,759	17,601
Shareholders' equity	10,678	14,767	15,356	16,988	18,805
Total equity & liabilities	15,776	20,824	25,437	28,548	31,460

Per-share data					
	FY2007	FY2008	FY2009	FY2010E	FY2011E
MF EPS (INR)	9.9	11.6	11.9	12.3	13.8
Growth, %	15.3	17.0	3.1	3.1	12.4
Book NAV/share (INR)	53.4	73.8	76.8	84.9	94.0
FDEPS (INR)	9.9	11.6	11.9	12.3	13.8
CEPS (INR)	13.1	4.6	24.3	18.5	20.8
CFPS (INR)	5.6	25.9	1.3	8.0	10.9
DPS (INR)	1.5	2.5	3.0	3.5	4.0

Financial structure					
	FY2007	FY2008	FY2009	FY2010E	FY2011E
Total debt/Equity (%)	17.5	17.3	34.1	36.7	38.5
Net debt/Equity (%)	16.7	16.6	33.3	33.6	35.7

Global

Profitability, Productivity, Liquidity and Valuation Ratios						
	FY2007	FY2008	FY2009	FY2010E	FY2011E	
Return on assets (%)	14.0	25.4	5.2	9.6	9.7	
Return on equity (%)	20.2	18.2	15.8	15.2	15.4	
Return on Invested capital (%)	23.2	23.1	18.5	19.6	19.4	
RoIC/Cost of capital (x)	2.8	2.8	2.2	2.3	2.2	
RoIC - Cost of capital (%)	14.9	14.8	9.9	11.0	10.7	
Return on capital employed (%)	18.0	31.8	7.1	14.4	14.7	
Cost of capital (%)	8.3	8.3	8.6	8.6	8.6	
RoCE - Cost of capital (%)	9.7	23.6	(1.5)	5.8	6.0	
Asset turnover (x)	0.9	0.8	1.1	1.1	1.1	
Sales/Total assets (x)	0.7	0.6	0.7	0.7	0.7	
Sales/Net FA (x)	1.1	1.1	1.4	1.6	1.6	
Receivable days	113.5	89.8	82.8	91.6	97.1	
Inventory days	59.7	62.0	72.1	68.3	70.7	
Payable days	99.3	83.1	59.2	58.8	49.6	
Current ratio (x)	1.6	1.3	1.0	1.1	1.1	
Quick ratio (x)	1.1	0.9	0.6	0.7	0.7	
Interest cover (x)	21.2	19.9	12.5	10.9	11.3	
Dividend cover (x)	6.6	4.6	4.0	3.5	3.5	
PER (x)	22.2	18.9	18.4	17.8	15.9	
PEG (x) - y-o-y growth	1.5	1.1	5.9	5.8	1.3	
Price/Book (x)	4.1	3.0	2.9	2.6	2.3	
Yield (%)	0.7	1.1	1.4	1.6	1.8	
EV/Net sales (x)	4.6	4.4	3.0	2.5	2.3	
EV/EBITDA (x)	16.6	15.6	14.7	12.7	11.3	
EV/EBIT (x)	16.6	15.6	14.7	12.7	11.3	
EV/CE	3.6	2.8	2.8	2.6	2.4	
EV/IC (x)	4.2	3.6	3.3	2.8	2.5	

Source: Company, MF Global India Research Estimates



vbhatnagar@mfglobal.com

jrowsell@@mfglobal.com

Vineet Bhatnagar James Rowsell Sajid Khalid

Managing Director

Global Head - Institutional Equities & Derivatives

Head - Institutional Equities 91-22-6667 9972 sakhalid@mfglobal.com Jignesh Shah Head - Equity Derivatives 91-22-6667 9735 ishah@mfglobal.com Equity Research 91-22-6667 9950 aldalal@mfglobal.com Alok Dalal Pharmaceuticals Ambrish Mishra Automobiles & Auto Component 91-22-6667 9758 amishra@mfqlobal.com 91-22-6667 9759 amahawar@mfglobal.com Amit Mahawar Engineering & Capital Goods Anjali Verma Economist 91-22-6667 9969 anverma@mfglobal.com aagarwal@mfglobal.com Avishek Agarwal Logistics & Shipping 91-22-6667 9986 Deepali Gautam 91-22-6667 9974 dgautam@mfglobal.com Power dsohani@mfglobal.com Real Estate 91-22-6667 9965 Dipesh Sohani Oil & Gas / Fertiliser ganand@mfglobal.com Gauri Anand 91-22-6667 9943 Kapil Bagaria Midcap 91-22-6667 9987 kbagaria@mfglobal.com Kunal Motishaw Metals 91-22-6667 9996 kmotishaw@mfglobal.com Manish Agarwalla Banking 91-22-6667 9962 magarwalla@mfglobal.com Naveen Kulkarni, FRM nkulkarni@mfglobal.com Telecom & FMCG 91-22-6667 9947 Nimesh Mistry IT Services 91-22-6667 9768 nmistry@mfglobal.com Ritwik Rai Media 91-22-6667 9766 rrai@mfglobal.com Vaibhav Agarwal Cement 91-22-6667 9967 vagarwal@mfglobal.com Aravind Manickam **Research Associate** 91-22-6667 9992 amanickam@mfglobal.com Ennette Fernandes Research Associate 91-22-6667 9764 efernandes@mfglobal.com Sapna Shah Research Associate 91-22-6667 9758 sapshah@mfglobal.com Saurabh Rathi **Research Associate** 91-22-6667 9951 srathi@mfglobal.com Shubhangi Agrawal **Research Associate** 91-22-6667 9964 sagrawal@mfglobal.com Quant Analyst Shikha Khurana 91-22-6667 9948 skhurana@mfglobal.com Ganesh Deorukhkar Production 91-22-6667 9756 gdeorukhkar@mfglobal.com rkalloor@mfglobal.com Roshni Kalloor Editor 91-22-6667 9762 Institutional Cash Equity Sales Kartik Broker Equity Sales 91-22-6667 9934 kbroker@mfglobal.com Kinshuk Tiwari Equity Sales 91-22-6667 9946 ktiwari@mfglobal.com Nasir Mohamed Equity Sales - UAE nmohamed@mfglobal.com 009714 3325052 / 91-22-6667 9973 Sheetal Gandhi Equity Sales - US 91-22-6667 9944 sgandhi@mfglobal.com Institutional Cash Equity Sales Trading

csavla@mfglobal.com rashar@mfglobal.com 91-22-6667 9749 Chetan Savla Sales Trader Rajesh Ashar Sales Trader 91-22-6667 9746 Sales Trader 91-22-6667 9747 skamath@mfglobal.com Sunil Kamath Institutional Cash Equity Dealing 91-22-6667 9945 cbabaria@mfglobal.com Chetan Babaria Dealer Mayur Shah 91-22-6677 9945 Dealer mshah@mfqlobal.com Sagar Shah Dealer 91-22-6677 9945 sagshah@mfglobal.com

Rating Rationale

BUY and SELL recommendations are used to draw attention to stocks, which we believe are under-priced or over-priced by circa 15%, that is, price differential of +/- 15% between our price target and the market price. Stocks which do not achieve this price differential are NEUTRAL. Price targets are established in the context of a flat market.

sclosures and Disclaimers

Disclosures and Disclaimers

WF Global Sify Securities India Pvt. Ltd. has three independent equity research groups: Institutional Equities, Institutional Equities Derivatives and Private Client Group. This report has been
prepared by Institutional Equities Research. The views and opinions expressed in this document may or may not match or may be contrary at times with the views, estimates, rating, target price
of the other equity research groups of MF Global Sify Securities India Pvt. Ltd.
This report is issued by MF Global Sify Securities India Pvt. Limited which is regulated by SEBI. MF Global Sify Securities India Pvt. Ltd.
to "MFGSSIPL" or "Firm" in this report shall mean MF Global Sify Securities India Pvt. Limited unless otherwise stated. This report is prepared and distributed by MFGSSIPL for information
purposes only and neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the
purchase or sale of any security, investment or derivatives. The information and opinions contained in the Report were considered by MFGSSIPL by valid when all reasonable steps to ensure
that this information provided to MFGSSIPL by third parties. The source of such information will usually be disclosed in the report. Whilst MFGSSIPL has taken all reasonable steps to ensure
that this information is correct, MFGSSIPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading
apast performance is not necessarily a guide to future performance.
This report does not have repared to the purpore.

the or her own risk and MEGSSIPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to ture performance.
 This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax and financial advisors and reach their own regarding thrue propriateness of investing in any securities or investment strategies discussed or investment analysis with their own legal, tax and financial advisors and reach their own regarding thrue propriateness of investing in any securities or investment strategies discussed or investment analysis with the buy or sell the Securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe are reliable. MF Global Sity Securities India Pvt. Ltd. or any of its group companies do not guarantee that such information is accurate or complete and it should not be relied indicationers and disclaimers must be read in conjunction with the research report is available on request.
 Certifications: The research naalyst(s) who prepared this research report of which it forms part. Receipt and use of the research naalyst(s) endocures and/or securities that the analyst tave to known conflict of interest and no part of the research report.
 Independence: MF Global Sity Securities India P. Ltd. An an investment banking reliationship with, and has not received any compensation was, is or will be directly endocure in this research report.
 Independence: MF Global Sity Securities India P. Ltd. has not had an investment banking reliationship with, and has not received any compensation for investement banking services from the subject issues from the subject

MF Global Sify Securities India Pvt. Limited 2nd Floor, C-Block, Modern Centre, Mahalaxmi, Mumbai-400 011